Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Add filters

Document Type
Year range
Nat Commun ; 12(1): 814, 2021 02 05.
Article in English | MEDLINE | ID: covidwho-1065864


On the basis of Covid-19-induced pulmonary pathological and vascular changes, we hypothesize that the anti-vascular endothelial growth factor (VEGF) drug bevacizumab might be beneficial for treating Covid-19 patients. From Feb 15 to April 5, 2020, we conducted a single-arm trial (NCT04275414) and recruited 26 patients from 2-centers (China and Italy) with severe Covid-19, with respiratory rate ≥30 times/min, oxygen saturation ≤93% with ambient air, or partial arterial oxygen pressure to fraction of inspiration O2 ratio (PaO2/FiO2) >100 mmHg and ≤300 mmHg, and diffuse pneumonia confirmed by chest imaging. Followed up for 28 days. Among these, bevacizumab plus standard care markedly improves the PaO2/FiO2 ratios at days 1 and 7. By day 28, 24 (92%) patients show improvement in oxygen-support status, 17 (65%) patients are discharged, and none show worsen oxygen-support status nor die. Significant reduction of lesion areas/ratios are shown in chest computed tomography (CT) or X-ray within 7 days. Of 14 patients with fever, body temperature normalizes within 72 h in 13 (93%) patients. Relative to comparable controls, bevacizumab shows clinical efficacy by improving oxygenation and shortening oxygen-support duration. Our findings suggest bevacizumab plus standard care is highly beneficial for patients with severe Covid-19. Randomized controlled trial is warranted.

Bevacizumab/therapeutic use , COVID-19/drug therapy , SARS-CoV-2/drug effects , Aged , Angiogenesis Inhibitors/therapeutic use , Body Temperature/drug effects , COVID-19/virology , China , Female , Fever/prevention & control , Humans , Italy , Male , Middle Aged , SARS-CoV-2/physiology , Treatment Outcome
J. Xi'An Jiaotong Univ. Med. Sci. ; 4(41): 492-496, 20200705.
Article in Chinese | WHO COVID, ELSEVIER | ID: covidwho-684024


Objective To evaluate the clinical and CT manifestations of coronavirus disease 2019 (COVID-19). Methods Serial clinical and CT data of 11 patients with confirmed COVID-19 were retrospectively analyzed. These data were collected in The Second Affiliated Hospital of Xi'an Jiaotong University from January 24 to February 9, 2020. There were 6 males and 5 females, aged from 17 to 64 years old, with the mean age of 42.27±15.67. Results A majority of the patients fell into mild type and only one was of severe type. Clinical manifestations were mainly fever, fatigue, and dry cough. For laboratory tests, the patients' lymphocyte and eosinophil counts decreased, while their C-reactive protein concentration increased. In terms of CT findings, 7 patients showed bilateral subpleural involvement. The ground glass opacity (GGO) was common in CT findings. Typical crazy paving sign, air bronchogram and halo sign were also found. During the progression of the disease, GGO might be associated with pulmonary consolidation. No enlarged lymph nodes or pleural effusion were seen in all the patients. Conclusion Patients with COVID-19 have distinctly characteristic chest CT manifestations and laboratory examination findings, which play a vital role in diagnosis and prognosis of the disease.